Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Publication|Articles|November 2, 2026
- November 2026
- Volume 92
- Issue 11
Advocating for Pharmacy Starts With Policy
Author(s)Mike Hennessy Jr, Chairman and CEO
Fact checked by: Tracy Ann Politowicz
Pharmacists have shown they can safely do more for patients. Now regulation and reimbursement have to catch up.
Advertisement
Advertisement
Pharmacy practice does not happen in a vacuum. Every service a pharmacist provides, from administering a vaccine to a medication therapy management (MTM) consult, sits inside a web of state regulations, payer policies, and reimbursement structures that often have little to do with clinical judgment and everything to do with where a pharmacy is located. Advocating for fair reimbursement starts with recognizing just how much of pharmacists’ daily work is shaped by forces outside the pharmacy itself.
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Advertisement
Advertisement